secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001104659-22-085865
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood Q2 2022 GAAP net income $37M; LINZESS Rx demand up 9% YoY; guidance reiterated
--------------------------------------------------------------------------------

- GAAP net income of $37M ($0.21 diluted EPS); adjusted EBITDA of $56M; total revenue $97.2M, down 7% YoY.
- LINZESS EUTRx prescription demand grew 9% year-over-year in Q2 2022.
- Completed $75M share repurchase program and repaid remaining 2022 Convertible Notes in cash.
- Reiterated 2022 guidance: low single-digit % LINZESS net sales growth, total revenue $420-$430M, adjusted EBITDA >$250M.
- Phase 3 pediatric linaclotide study for functional constipation expected to readout in Q3 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465922085865/0001104659-22-085865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465922085865/tm2222410d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-085865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer